{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:01:03Z","timestamp":1783573263284,"version":"3.55.0"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,3,12]],"date-time":"2012-03-12T00:00:00Z","timestamp":1331510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Photoderm Photoimm Photomed"],"published-print":{"date-parts":[[2012,4]]},"abstract":"Summary<\/jats:title>Background\/Purpose<\/jats:title>Narrow\u2010band ultraviolet B<\/jats:styled-content> (NB\u2010UVB<\/jats:styled-content>) is considered the most effective and safe initial treatment for moderate\u2010to\u2010severe vitiligo but phototoxicity and possible carcinogenicity are the reported side effects. Ultraviolet A<\/jats:styled-content>1 (UVA1<\/jats:styled-content>) phototherapy has overlapping biological effects to NB\u2010UVB<\/jats:styled-content> and is relatively free of side effects associated with other phototherapy regimens.<\/jats:p><\/jats:sec>Methods<\/jats:title>Forty patients with vitiligo were included in this prospective, randomized controlled comparative clinical trial. Twenty patients received NB\u2010UVB<\/jats:styled-content> and 20 received UVA1<\/jats:styled-content> three times weekly for 12 weeks. The UVA1<\/jats:styled-content> group was divided into two subgroups. Ten patients received moderate and 10 received low dose of UVA1<\/jats:styled-content>. Serum samples were collected before and after 36 sessions to assess soluble interleukin 2 receptor level. Patients were clinically evaluated before therapy then monthly according to V<\/jats:styled-content>itiligo A<\/jats:styled-content>rea S<\/jats:styled-content>coring I<\/jats:styled-content>ndex (VASI<\/jats:styled-content>) and V<\/jats:styled-content>itiligo E<\/jats:styled-content>uropean T<\/jats:styled-content>ask F<\/jats:styled-content>orce (VETF<\/jats:styled-content>) scores. In addition, extent of response was determined by a blinded dermatologist comparing before and after therapy photographs. Pattern of response and side effects were recorded.<\/jats:p><\/jats:sec>Results<\/jats:title>NB\u2010UVB<\/jats:styled-content> was superior to UVA1<\/jats:styled-content> with a significant difference in blinded dermatological assessment (P<\/jats:styled-content><\/jats:italic>\u2009<\u20090.001), percentage change in VASI<\/jats:styled-content> score (P<\/jats:styled-content><\/jats:italic>\u2009<\u20090.001) and percentage change in VETF<\/jats:styled-content> area score (P<\/jats:styled-content><\/jats:italic>\u2009=\u20090.001). No significant difference in side effects was observed between both groups. Comparing UVA1<\/jats:styled-content> subgroups, better response in moderate\u2010dose group was found as regard to percentage change in VASI<\/jats:styled-content> (P<\/jats:styled-content><\/jats:italic>\u2009<\u20090.001) and percentage change in VETF<\/jats:styled-content> area score (P<\/jats:styled-content><\/jats:italic>\u2009=\u20090.001), while no significant difference was found in blinded dermatological assessment (P<\/jats:styled-content><\/jats:italic>\u2009=\u20090.121).<\/jats:p><\/jats:sec>Conclusion<\/jats:title>NB\u2010UVB<\/jats:styled-content> phototherapy remains to be an effective and safe therapeutic option in vitiligo. Response to UVA1<\/jats:styled-content> in vitiligo seems to be dose dependent and seems to be of limited value in treatment of vitiligo as a monotherapy. Further studies combining it with other lines of therapy such as systemic steroids may prove beneficial.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1600-0781.2011.00643.x","type":"journal-article","created":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T03:16:17Z","timestamp":1331608577000},"page":"84-90","source":"Crossref","is-referenced-by-count":29,"title":["A comparative study on efficacy of UVA1<\/scp> vs. narrow\u2010band UVB<\/scp> phototherapy in the treatment of vitiligo"],"prefix":"10.1111","volume":"28","author":[{"given":"Bakr Mohamed","family":"El\u2010Zawahry","sequence":"first","affiliation":[{"name":"Department of Dermatology Kasr El\u2010Ainy University Hospital Cairo University Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia Ahmed","family":"Bassiouny","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kasr El\u2010Ainy University Hospital Cairo University Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehab Mohamed","family":"Sobhi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kasr El\u2010Ainy University Hospital Cairo University Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Abdel\u2010Aziz","sequence":"additional","affiliation":[{"name":"Department of Dermatology El\u2010Talabah Hospital Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naglaa Sameh","family":"Zaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kasr El\u2010Ainy University Hospital Cairo University Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawoud Fakhry","family":"Habib","sequence":"additional","affiliation":[{"name":"Department of Biochemistry National Research Center Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia Mamdouh","family":"Shahin","sequence":"additional","affiliation":[{"name":"Department of Dermatology National Research Center Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2007.04.008"},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1468-3083.2006.02035.x","article-title":"Comparison of systemic PUVA and NB\u2010UVB in the treatment of vitiligo: an open prospective study","volume":"21","author":"Bhatnagar A","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05261.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2006.00229.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2008.00328.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(98)00070-X"},{"key":"e_1_2_6_8_1","first-page":"109","article-title":"Serum levels of soluble IL\u20102R in vitiligo patients in UAE","volume":"37","author":"Galadari I","year":"2005","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(99)00029-8"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2006.02907.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.6.677"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0749.2006.00355.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90152-G"},{"key":"e_1_2_6_14_1","first-page":"2370","article-title":"Vitiligo loss of cutaneous pigmentation","volume":"126","author":"Sitek JC","year":"2006","journal-title":"Tidsskr Nor Laegeforen"},{"key":"e_1_2_6_15_1","first-page":"839","volume-title":"Fitzpatrick's dermatology in general medicine","author":"Ortonne JP","year":"2003"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-008-0904-8"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0749.2003.00032.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0749.2003.00023.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2008.00528.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01413.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2007.00278.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.11.s.1.9.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jidsp.5640185"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63260-9"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.04427.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00403-002-0332-0","article-title":"Apoptosis of human dermal endothelial cells as a potential side effect following therapeutic administration of UVA1 irradiation: preliminary results","volume":"294","author":"Breuckmann F","year":"2002","journal-title":"Arch Dermatol Res"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02063.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh643"},{"key":"e_1_2_6_29_1","first-page":"1555","volume-title":"Fitzpatrick's dermatology in general medicine","author":"McGregor J","year":"1999"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08881.x"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2006.00222.x"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2005.tb00847.x"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12709595"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0749.1994.tb00049.x"}],"container-title":["Photodermatology, Photoimmunology & Photomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0781.2011.00643.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0781.2011.00643.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:18:01Z","timestamp":1698639481000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0781.2011.00643.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,12]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1111\/j.1600-0781.2011.00643.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0781.2011.00643.x","archive":["Portico"],"relation":{},"ISSN":["0905-4383","1600-0781"],"issn-type":[{"value":"0905-4383","type":"print"},{"value":"1600-0781","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,12]]}}}